Britain and America have concluded a significant commercial pact that will keep zero tariffs on UK drug exports entering the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the public health system. This move guarantees that duties on these vital goods will be held at zero for a timeframe of the next three years.
This agreement follows recent threats to hike duties on patented drug imports, with increases floated as high as double the cost.
"This agreement between the UK reinforces the international landscape for innovative medicines and brings much-needed balance to U.S.–U.K. drug exports," a release said.
Commercial Importance
Medicines represent one of the UK's biggest goods shipped to the United States, which is by far the biggest destination for major British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This deal safeguards employment, stimulates investment and paves the way for the UK to emerge as a international leader for life sciences," a minister commented.
Detailed British Pledges
The agreement includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to raise total NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. In the past, repayments exceeded 20%.
Industry Background
The deal follows a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by assertions that US consumers were charged several times more for the identical medicines than consumers in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been halted or scrapped, while substantial expansions have been directed toward projects in the United States.
The Science Minister stated that the NHS had to spend more on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
